Thinking by metaphor, fast and slow: Deliberate Metaphor Theory offers a new model for metaphor and its comprehension.

The immense increase in metaphor theory and research over the past decades is posing a threat of fragmentation to the field, which has been responded to by calls for new and more encompassing approaches to virtually all aspects metaphorical. This article argues that the opposite response may be more productive. By focusing on a different way of theorizing metaphor and its comprehension, existing theories and data can be re-ordered in an alternative and coherent way, which moreover breaks new grounds in tying up both with a general theory for all utterance comprehension as well as a general theory for all cognition as involving fast and slow thinking.

Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model.

Pharmacological approaches offer a non-invasive and promising option for fertility preservation in young female cancer patients undergoing gonadotoxic therapy. The GnRH-agonists are the only clinically available drugs in this indication, but their use and mechanisms of protection are still controversial. Recently, we have investigated new targeted drugs based on microRNA (miRNA) replacement therapy, and have identified the let-7a miRNA as candidate for fertility preservation strategies.

Treatment Challenges When Stopping Denosumab.

Introduction Denosumab is commonly used to treat osteoporosis. However, discontinuation results in rebound bone loss and increased vertebral fracture risk. We report a clinical case series, illustrating the dilemma in deciding the best treatment should denosumab be stopped.

Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.

More than 10% of women diagnosed with breast cancer during reproductive age carry hereditary germline pathogenic variants in high-penetrance BRCA genes or in others genes involved in DNA repair mechanisms such as PALB2, BRIP or ATM. Anticancer treatments may have an additional negative impact on the ovarian reserve and subsequently on the fertility of young patients carrying such mutations. Recently, the combination of carboplatin and paclitaxel is being recommended to these BRCA-mutated patients as neoadjuvant therapy.